The First affiliated hospital of Suzhou university
Suzhou, China
NCT Number: NCT05873426
This study is a single-center, open-label, and single-dose clinical study to evaluate the mass balance, biotransformation and pharmacokinetics of [14C]ZSP1273 in healthy Chinese male participants, revealing the overall pharmacokinetic characteristics of ZSP1273.
Looking for future studies?
Notify Me18 year–45 year
Male
Interventional
Phase 1
Suzhou, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
600 mg suspension containing 50μCi of [14C]ZSP1273
Time frame: Up to 14 days from the start of administration.
Time frame: Up to 14 days from the start of administration.
Time frame: Up to 14 days from the start of administration.
Time frame: Up to 14 days from the start of administration.
Time frame: Up to 14 days from the start of administration.
Time frame: Up to 23 days (approx) from the start of administration.
Time frame: Up to 14 days from the start of administration.
Guangdong Raynovent Biotech Co., Ltd
Industry
Single-center, Open-label, Non-randomized and Single-dose Clinical Trial to Explore the Mass Balance of Oral Suspension of 600mg [14C]ZSP1273
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07560150
Insulin Aspart, Pharmacodynamics
Chula Vista, California, United States
View Trial DetailsNCT05142592
Pharmacokinetics, Safety Issues
Portland, Oregon, United States
View Trial DetailsNCT03911050
Human Health, Pharmacokinetics
Kannapolis, North Carolina, United States
View Trial DetailsNCT05328778
Pharmacokinetics
Guangzhou, Guangdong, China
View Trial Details